Tate, S.J.; Van de Sande, L.; Ceelen, W.P.; Torkington, J.; Parker, A.L.
The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics 2021, 13, 2043.
https://doi.org/10.3390/pharmaceutics13122043
AMA Style
Tate SJ, Van de Sande L, Ceelen WP, Torkington J, Parker AL.
The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics. 2021; 13(12):2043.
https://doi.org/10.3390/pharmaceutics13122043
Chicago/Turabian Style
Tate, Sophia J., Leen Van de Sande, Wim P. Ceelen, Jared Torkington, and Alan L. Parker.
2021. "The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses" Pharmaceutics 13, no. 12: 2043.
https://doi.org/10.3390/pharmaceutics13122043
APA Style
Tate, S. J., Van de Sande, L., Ceelen, W. P., Torkington, J., & Parker, A. L.
(2021). The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics, 13(12), 2043.
https://doi.org/10.3390/pharmaceutics13122043